Omega Fund Management Increases Stake in Bicara Therapeutics to Nearly 29% of Portfolio
On May 15, 2026, Omega Fund Management disclosed a purchase of 187,500 shares of Bicara Therapeutics (NASDAQ:BCAX), increasing its position's value by $3.23 million and raising the stake to nearly 29% of its portfolio as reported in an SEC filing. The stock has risen approximately 50% over the past year.
Tickers: $BCAX
Topics: 13F Filings Biotech Stock Ownership